Strong Q4 seen for pharma firms, EME, domestic demand key drivers
Robust demand from domestic and emerging-markets abroad, increased currency of specialty products and price hikes are expected to have allowed pharma companies to post healthy topline and bottomline growth in the fourth quarter of FY24. As per ICICI …